Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FCN-338 in Relapsed/Refractory CLL/SLL
NCT04682808Phase 1Active, not recruiting
- Sponsor
- Fochon Biosciences
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LOXO-338 in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Fochon Biosciences. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose and Recommended Phase 2 Dose up to 24 months and 2 more. Started May 2021; status: active, not recruiting.
02
Drugs
LOXO-338
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04682808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04682808.